<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290783</url>
  </required_header>
  <id_info>
    <org_study_id>ACO-002</org_study_id>
    <nct_id>NCT01290783</nct_id>
  </id_info>
  <brief_title>Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC</brief_title>
  <acronym>FOLF(HA)iri</acronym>
  <official_title>Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alchemia Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alchemia Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial design:

        -  Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with &quot;Hyaluronic
           acid-Irinotecan&quot; or &quot;HA-Irinotecan&quot;) regimen.

        -  Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.

        -  Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria,
           Poland, Serbia, Russia, Ukraine and the United Kingdom).

        -  Dosing regimen:

             -  Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in
                patients &gt; 75 years of age, the irinotecan and HA-Irinotecan dose in must be
                reduced to 150 mg/m2).

             -  Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with
                irinotecan.

             -  5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days
                (total 2400 mg/m2 over 46-48 hours) continuous infusion.

             -  Repeat every 2 weeks for 8 months.

        -  Patient accrual over approximately 12-14 months.

        -  Monitoring to 18 months post-randomization.

        -  390 patients.

        -  Progression Free Survival (PFS) primary endpoint.

        -  Safety analysis on the initial 20 patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 20 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>After initial 20 patients receive 2 cycles, then 6 monthly thereafter.</time_frame>
    <description>Diarrhea and haematology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLF(HA)iri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irintoecan</intervention_name>
    <description>Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients &gt; 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks.
8 months of treatment.</description>
    <arm_group_label>FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HA-Irinotecan solution for Infusion</intervention_name>
    <description>HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients &gt; 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks
8 months of treatment.</description>
    <arm_group_label>FOLF(HA)iri</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic colorectal cancer with disease progression after first or second line
             chemotherapy

          -  Irinotecan naïve.

          -  ECOG performance status of 0 or 1.

          -  Measurable disease, i.e. at least one measurable metastatic lesion (spiral CT or MRI).

          -  Histological proof of colorectal cancer.

          -  18 years of age and older.

          -  Adequately recovered from and at least 4 weeks after recent surgery or chemotherapy.

          -  Women of child-bearing potential (WOCBP) and male partners of WOCBP must agree to use
             adequate contraception.

          -  Patient consent obtained and signed according to local and/or national ethics.

          -  CT or MRI scan of chest/abdomen/pelvis within 21 days prior to randomization.

          -  Hematology done within 14 days prior to randomization.

          -  Chemistry done within 14 days prior to randomization.

        Exclusion Criteria:

          -  History of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in-situ cancer of the cervix, or other solid tumors curatively
             treated with no evidence of disease for &gt; 5 years.

          -  Locally advanced or recurrent disease only.

          -  Unsuitability for irinotecan including known Gilbert's syndrome, active inflammatory
             bowel disease or chronic diarrhea greater than or equal to grade 2.

          -  Abdominal or pelvic radiation therapy within the last 12 months.

          -  Women who are pregnant or breastfeeding.

          -  Any condition (e.g., psychological, geographical) that would render the protocol
             treatment dangerous.

          -  Significant cardiac disease.

          -  Untreated or symptomatic brain or central nervous system (CNS).

          -  Presence of pleural effusion or ascites requiring therapeutic thoracocentesis or
             paracentesis.

          -  Current partial or complete bowel obstruction.

          -  Concomitant active infection.

          -  Enrolled in any other investigational trial, unless treatment in that trial has been
             discontinued at least 30 days prior to signing the Informed Consent for the ACO-002
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gibbs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, Underhill CR, Fox RM, Clavant SP, Leung J, Pho M, Brown TJ. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother Pharmacol. 2011 Jan;67(1):153-63. doi: 10.1007/s00280-010-1303-3. Epub 2010 Mar 24.</citation>
    <PMID>20333384</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRC</keyword>
  <keyword>CRC</keyword>
  <keyword>colorectal</keyword>
  <keyword>irinotecan</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>Hyaluronan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 28, 2015</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

